A Nature Communications paper described a Granzyme B‑mimetic nanozyme packaged in targeted nanovesicles that induces apoptosis in cancer cells. The nanozyme architecture mimics the protease activity of immune‑cell granule enzymes, providing a synthetic route to intracellular proteolytic attack on tumors. The team demonstrated targeted delivery and antitumor activity in preclinical models, positioning nanozymes as a programmable complement to biological immune effectors and a potential route to tumor‑directed cytotoxicity with engineered specificity.